2.50
Hdl Handle:
http://hdl.handle.net/10541/86501
Title:
Tamoxifen versus the newer SERMs: what is the evidence?
Authors:
Howell, Anthony ( 0000-0002-3879-5991 )
Affiliation:
CRC Department of Medical Oncology, University of Manchester, Christie Hospital, UK.
Citation:
Tamoxifen versus the newer SERMs: what is the evidence? 2000, 11 Suppl 3:255-65 Ann. Oncol.
Journal:
Annals of Oncology
Issue Date:
2000
URI:
http://hdl.handle.net/10541/86501
PubMed ID:
11079150
Type:
Article
Language:
en
ISSN:
0923-7534
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorHowell, Anthonyen
dc.date.accessioned2009-11-19T15:28:30Z-
dc.date.available2009-11-19T15:28:30Z-
dc.date.issued2000-
dc.identifier.citationTamoxifen versus the newer SERMs: what is the evidence? 2000, 11 Suppl 3:255-65 Ann. Oncol.en
dc.identifier.issn0923-7534-
dc.identifier.pmid11079150-
dc.identifier.urihttp://hdl.handle.net/10541/86501-
dc.language.isoenen
dc.subjectBreast Canceren
dc.subject.meshBreast Neoplasms-
dc.subject.meshDrug Evaluation-
dc.subject.meshEvidence-Based Medicine-
dc.subject.meshHumans-
dc.subject.meshMolecular Structure-
dc.subject.meshSelective Estrogen Receptor Modulators-
dc.subject.meshTamoxifen-
dc.titleTamoxifen versus the newer SERMs: what is the evidence?en
dc.typeArticleen
dc.contributor.departmentCRC Department of Medical Oncology, University of Manchester, Christie Hospital, UK.en
dc.identifier.journalAnnals of Oncologyen
All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.